Q1 2025 Medistim ASA Earnings Call Transcript

May 9, 2025 / 07:00 AM GMT

Release Date Price: kr196.5 (+14.58%)

Transcript

Key Points

Positve

Medistim ASA (FRA:MD1) reported a record-breaking quarter with revenues reaching 181.5 million NOK, marking a 35.7% growth compared to the previous year.
The company achieved an 84% increase in operating profit, driven by strong growth in its own product sales.
Sales in the Asia Pacific region surged by almost 63%, showcasing significant market expansion.
The company declared a dividend payout of 6 NOK per share, totaling 109.6 million NOK, reflecting strong financial health.
Medistim ASA (FRA:MD1) has strengthened its commercial operations with organizational changes, aiming to optimize strategies and share best practices across regions.

Negative

Despite strong profits, cash flow from operations was only 18.8 million NOK, impacted by pre-payment of taxes and increased working capital.
The company experienced a negative net finance result of just under 2.5 million NOK due to currency fluctuations.
Inventory levels increased, particularly for third-party products, due to ongoing projects like equipping a new hospital, which may affect short-term cash flow.
Accounts receivable increased by 23 million NOK, reflecting the rise in sales but also indicating potential collection challenges.
The recurring revenue percentage decreased slightly to 67.7% this quarter, influenced by high capital sales, which may affect future revenue stability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MEDI.OL - Medistim ASA
Q1 2025 Medistim ASA Earnings Call
May 09, 2025 / 07:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Very good morning and welcome to Medicine's first quarter 2025 Resolve presentation.

My name is Karista, and together with the CFO Thomas Jacobsen, we are going to take you through the first quarter's results.

And we will start with the highlights, but before that, we like to also remind everyone on Medicine's track record, which has been very positive, showing a consistent delivery of sales growth, profitable sales growth over the years.

And as the last 12 months, 2025 columns are indicating, we can already from this graph disclose that Q1 was a very strong start to 2025 for the company.

So let's go directly into the highlights for the 1st quarter.

So This is really a quarter when the business is

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.